HK1244213A1 - 预防或治疗脂肪肝的药物组合物 - Google Patents

预防或治疗脂肪肝的药物组合物 Download PDF

Info

Publication number
HK1244213A1
HK1244213A1 HK18103734.5A HK18103734A HK1244213A1 HK 1244213 A1 HK1244213 A1 HK 1244213A1 HK 18103734 A HK18103734 A HK 18103734A HK 1244213 A1 HK1244213 A1 HK 1244213A1
Authority
HK
Hong Kong
Prior art keywords
acid
mannitol
liver
eriodictyol
sucralose
Prior art date
Application number
HK18103734.5A
Other languages
English (en)
Chinese (zh)
Inventor
胡幼圃
何欣恬
吴永恩
唐熙卉
吳永恩
Original Assignee
欣耀生医股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 欣耀生医股份有限公司 filed Critical 欣耀生医股份有限公司
Publication of HK1244213A1 publication Critical patent/HK1244213A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B2/00—Preservation of foods or foodstuffs, in general
    • A23B2/70—Preservation of foods or foodstuffs, in general by treatment with chemicals
    • A23B2/725—Preservation of foods or foodstuffs, in general by treatment with chemicals in the form of liquids or solids
    • A23B2/729—Organic compounds; Microorganisms; Enzymes
    • A23B2/733—Compounds of undetermined constitution obtained from animals or plants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Medical Informatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
HK18103734.5A 2015-11-19 2016-03-31 预防或治疗脂肪肝的药物组合物 HK1244213A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562257697P 2015-11-19 2015-11-19
US62/257,697 2015-11-19
PCT/CN2016/078039 WO2017084234A1 (zh) 2015-11-19 2016-03-31 预防或治疗脂肪肝的药物组合物

Publications (1)

Publication Number Publication Date
HK1244213A1 true HK1244213A1 (zh) 2018-08-03

Family

ID=58718029

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18103734.5A HK1244213A1 (zh) 2015-11-19 2016-03-31 预防或治疗脂肪肝的药物组合物

Country Status (7)

Country Link
US (1) US10925854B2 (cg-RX-API-DMAC7.html)
EP (1) EP3391881A4 (cg-RX-API-DMAC7.html)
JP (4) JP2018534323A (cg-RX-API-DMAC7.html)
CN (2) CN107613968A (cg-RX-API-DMAC7.html)
HK (1) HK1244213A1 (cg-RX-API-DMAC7.html)
TW (1) TWI711464B (cg-RX-API-DMAC7.html)
WO (1) WO2017084234A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201890810A1 (ru) * 2015-09-24 2018-11-30 Синью Фарма Инк. Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
CN110151787A (zh) * 2018-02-12 2019-08-23 玛旺干细胞医学生物科技股份有限公司 护肝组合物及其用途
TWI691719B (zh) * 2018-10-19 2020-04-21 香港商阿瓦隆 海帕波有限公司 半乳糖快速定量檢測系統及其應用
EP3991728A4 (en) * 2019-06-25 2023-08-09 National Hospital Organization HEPATIC FIBROSIS INHIBITING AGENT AND BROWN FAT CELL ACTIVATING AGENT WITH TAXIFOLINE
CN112471376A (zh) * 2020-11-02 2021-03-12 辽宁康汇医学临床研究有限公司 一种防治酒精性脂肪肝的固体饮料及其制备方法
CN113440514B (zh) * 2021-08-20 2022-09-09 中国农业科学院郑州果树研究所 含橙皮素的组合物及其制备降血糖药物的应用
CN117205159A (zh) * 2023-09-04 2023-12-12 中国医学科学院药用植物研究所 一种自纳米组合物及制备方法与应用
CN119184297A (zh) * 2024-09-18 2024-12-27 中国农业大学 葛根素及其衍生物调控des1改善肝脏脂质堆积及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4388328A (en) * 1981-10-15 1983-06-14 Warner-Lambert Company Sorbitol containing mixture encapsulated flavor
US5080910A (en) * 1990-05-15 1992-01-14 Werner-Lambert Company Stabilized chlorodeoxysugar sweetening agents in powder form and methods for preparing same
US5804165A (en) * 1996-07-24 1998-09-08 Arnold; Michael J. Antiplaque oral composition
WO1999053914A1 (en) * 1998-04-16 1999-10-28 Ajinomoto Co., Inc. Remedies for primary biliary cirrhosis
JP4824886B2 (ja) * 2001-09-11 2011-11-30 長岡香料株式会社 フルクトース吸収阻害剤、組成物、および食品
JP4203282B2 (ja) * 2002-08-26 2008-12-24 株式会社青粒 アブラナ科植物の抽出物とその用途
DE602004015966D1 (de) * 2003-04-03 2008-10-02 Hayashibara Biochem Lab Lipidregulierendes mittel und dessen verwendung
WO2006135084A1 (ja) * 2005-06-14 2006-12-21 Kurume University 脂肪性肝炎または脂肪肝の予防または治療薬
JP2007182405A (ja) * 2006-01-10 2007-07-19 Univ Kurume 脂肪性肝疾患の改善治療薬
WO2009028457A1 (ja) * 2007-08-29 2009-03-05 Shinshu University 非アルコール性脂肪肝炎治療薬
CN101683411B (zh) * 2008-09-24 2012-09-19 汪鋆植 海棠提取物在制备保肝药物或保健食品中的用途
CN101744865B (zh) * 2008-12-18 2012-07-25 山东福田药业有限公司 一种木糖醇护肝片的制备方法
JP2012520866A (ja) * 2009-03-17 2012-09-10 アプタリス・ファーマ・カナダ・インコーポレイテッド 高用量のウルソデオキシコール酸で非アルコール性脂肪性肝炎を治療する方法
TR200904862A1 (tr) * 2009-05-29 2010-12-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Sukraloz formülasyonu ve üretim prosesi
CN101933900A (zh) * 2009-07-02 2011-01-05 天津瑞普生物技术股份有限公司 一种用于防治禽类肝病的复方制剂及其制备方法
JP2011231078A (ja) * 2010-04-30 2011-11-17 Nagaoka Koryo Kk 非アルコール性脂肪性肝疾患の予防および／または治療に有効な経口摂取用組成物
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
US8969312B2 (en) * 2011-04-20 2015-03-03 National Defense Education And Research Foundation Low side effect pharmaceutical composition containing antituberculosis drugs
CN102908596B (zh) * 2011-08-05 2014-09-03 成都永康制药有限公司 一种治疗脂肪肝的中药组合物
BR102012033020A2 (pt) * 2011-12-22 2015-10-20 Int Flavors & Fragrances Inc composições para aumento da sensação de frescor
US20140274979A1 (en) * 2013-03-13 2014-09-18 Golden Biotechnology Corporation Method for the treatment of fatty liver disease
US10441560B2 (en) * 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
MX2015014956A (es) * 2013-04-29 2016-08-08 Chigurupati Tech Private Ltd Toxicidad reducida en bebidas alcoholicas.
CN103432528A (zh) * 2013-08-23 2013-12-11 冯庄明 一种治疗非酒精性脂肪肝的中药制剂
WO2015070396A1 (zh) * 2013-11-13 2015-05-21 财团法人国防教育研究基金会 无肝副作用的对乙酰胺基酚新复方组合
EA201890810A1 (ru) * 2015-09-24 2018-11-30 Синью Фарма Инк. Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение

Also Published As

Publication number Publication date
CN107613968A (zh) 2018-01-19
EP3391881A1 (en) 2018-10-24
TWI711464B (zh) 2020-12-01
US10925854B2 (en) 2021-02-23
JP2018534323A (ja) 2018-11-22
CN116440143A (zh) 2023-07-18
JP2023145714A (ja) 2023-10-11
TW201718015A (zh) 2017-06-01
JP2025124769A (ja) 2025-08-26
EP3391881A4 (en) 2020-03-11
US20180117003A1 (en) 2018-05-03
JP7690526B2 (ja) 2025-06-10
JP2021105037A (ja) 2021-07-26
WO2017084234A1 (zh) 2017-05-26

Similar Documents

Publication Publication Date Title
HK1244213A1 (zh) 预防或治疗脂肪肝的药物组合物
Zhou et al. Alpinetin improved high fat diet-induced non-alcoholic fatty liver disease (NAFLD) through improving oxidative stress, inflammatory response and lipid metabolism
Cai et al. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy
Yuan et al. Protective effect of resveratrol on kidney in rats with diabetic nephropathy and its effect on endoplasmic reticulum stress.
Lu et al. Apigenin reduces the excessive accumulation of lipids induced by palmitic acid via the AMPK signaling pathway in HepG2 cells
Wang et al. Isorhamnetin, the xanthine oxidase inhibitor from Sophora japonica, ameliorates uric acid levels and renal function in hyperuricemic mice
Lin et al. The chloroform extract of Cyclocarya paliurus attenuates high-fat diet induced non-alcoholic hepatic steatosis in Sprague Dawley rats
Zhang et al. Paeonia× suffruticosa Andrews leaf extract and its main component apigenin 7-O-glucoside ameliorate hyperuricemia by inhibiting xanthine oxidase activity and regulating renal urate transporters
Zhao et al. Phlorizin from Lithocarpus litseifolius [Hance] Chun ameliorates FFA-induced insulin resistance by regulating AMPK/PI3K/AKT signaling pathway
Gao et al. A refined-JinQi-JiangTang tablet ameliorates prediabetes by reducing insulin resistance and improving beta cell function in mice
bu Kang et al. A novel phenolic formulation for treating hepatic and peripheral insulin resistance by regulating GLUT4-mediated glucose uptake
Zhang et al. Trilobatin alleviates non-alcoholic fatty liver disease in high-fat diet plus streptozotocin-induced diabetic mice by suppressing NLRP3 inflammasome activation
Tian et al. Selegiline ameliorated dyslipidemia and hepatic steatosis in high-fat diet mice
Zhou et al. Schisandrin B inhibits inflammation and ferroptosis in S. aureus-induced mastitis through regulating SIRT1/p53/SLC7A11 signaling pathway
Cui et al. Effects of grape peel phenolics on lipid accumulation in sodium palmitate-treated HepG2 cells
CN107427489A (zh) 用于治疗非酒精性脂肪肝疾病的药物及应用
Gong et al. 6-Methyl flavone inhibits Nogo-B expression and improves high fructose diet-induced liver injury in mice
TWI634886B (zh) Compound composition for liver-free side effects with reduced liver fat for treating symptoms of non-alcoholic fatty liver disease (NAFLD)
Yotsumoto et al. Effects of carnitine palmitoyltransferase I inhibitors on hepatic hypertrophy
Abenavoli et al. Dietary Polyphenols and Non-Alcoholic Fatty Liver Disease. Nutrients 2021, 13, 494
KR20220002047A (ko) 지페노사이드 화합물을 포함하는 간 질환 예방 또는 치료용 조성물
HK40089284A (zh) 预防或治疗脂肪肝的药物组合物
US20210121383A1 (en) Composition for anti-aging
Guo et al. Inhibitory effect of aqueous extract of Scrophularia ningpoensis on β-cell pyroptosis in diabetic mice
Yang et al. The mechanism and targeted intervention of the HIF-1 pathway in improving atherosclerotic heart's sensitivity to ischemic postconditioning